

CITATION REPORT

List of articles citing

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

DOI: 10.1002/eji.200324181

European Journal of Immunology, 2004, 34, 336-44.

Source: <https://exaly.com/paper-pdf/37104306/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
802	.		
801	Efficacy of reovirus therapy combined with cyclophosphamide and gene-modified cell vaccines on tumors induced in mice by HPV16-transformed cells. 1992 , 33, 421		2
800	T-cell epitope peptide vaccines. 2004 , 3, 563-75		17
799	Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. 2004 , 94, 11-26		120
798	Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. 2004 , 200, 771-82		453
797	Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. 2004 ,		
796	Transforming growth factor ?? and the immunopathologic assessment of tolerance. 2004 , 9, 241-245		2
795	C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. 2005 , 65, 3374-9		46
794	Mechanisms of Central and Peripheral T-Cell Tolerance: An Update. 2005 , 32, 384-399		5
793	Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. 2005 , 106, 2018-25		414
792	The immunotherapy of prostate and bladder cancer. 2005 , 96, 728-35		12
791	Immunotherapy and chemotherapy--a practical partnership. 2005 , 5, 397-405		539
790	Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L. 2005 , 12, 198-205		62
789	Current immunotherapy of melanoma. 2005 , 5, 111-132		2
788	Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity. 2005 , 110, 119-29		62
787	Regulatory T cells and tumor immunity. 2005 , 54, 1153-61		75
786	CD4 T cells in tumor immunity. 2005 , 27, 37-48		72

785	Defensins--non-antibiotic use for vaccine development. 2005 , 6, 53-60	29
784	Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. 2005 , 102, 18538-43	1722
783	A role for fungal {beta}-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. 2005 , 201, 949-60	346
782	In contrast to effector T cells, CD4+CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. 2005 , 175, 32-6	143
781	Strategies of antigen-specific T-cell-based immunotherapy for cancer. 2005 , 20, 491-501	9
780	Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. 2005 , 65, 5027-30	74
779	Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. 2005 , 65, 9547-54	60
778	Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. 2005 , 65, 8059-64	152
777	Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. 2005 , 201, 1591-602	369
776	CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. 2005 , 202, 1075-85	687
775	Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology. 2005 , 4, 1645-52	26
774	The potential of exosomes in immunotherapy. 2005 , 5, 737-47	40
773	Metabolism and transport of oxazaphosphorines and the clinical implications. 2005 , 37, 611-703	137
772	Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. 2005 , 202, 919-29	592
771	The potential of exosomes in immunotherapy of cancer. 2005 , 35, 111-5	36
770	Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity. 2005 , 39, 105-12	87
769	Towards a therapeutic breast cancer vaccine: the next steps. 2005 , 4, 831-41	3
768	[Phenotypic and functional analysis of T lymphocytes in cancer patients]. 2005 , 25, 211-9	

767	Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. 2005 , 105, 2862-8	720
766	Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency. 2005 , 7, R326-35	35
765	Regulatory T cells in cancer. 2006 , 108, 804-11	563
764	Prophylaxis and treatment of acute graft-versus-host disease. 2006 , 43, 32-41	54
763	Immunotherapy of hepatocellular carcinoma. 2006 , 45, 868-78	64
762	In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. 2006 , 4, 52	93
761	Vaccination for treatment and prevention of cancer in animal models. 2006 , 90, 175-213	70
760	Cyclophosphamide augments inflammation by reducing immunosuppression in a mouse model of allergic airway disease. 2006 , 117, 635-41	35
759	Recent advances in the use of antigen-specific T cells for the treatment of cancer. 2006 , 1, 333-342	2
758	Insights into transcriptional regulation by FOXP3. 2006 , 11, 1607-19	12
757	Colon cancer and the immune system: the role of tumor invading T cells. 2006 , 12, 7233-8	70
756	Immunotherapy as part of a multidisciplinary approach to melanoma treatment. 2006 , 11, 1-14	17
755	Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy. 2006 , 107, 381-8	30
754	Dysfunctional T regulatory cells in multiple myeloma. 2006 , 107, 301-4	188
753	In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. 2006 , 107, 3940-9	243
752	Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine. 2006 , 17, 1045	
751	Manipulating Immunological Checkpoints to Maximize Antitumor Immunity. 2006 , 331-353	
750	Manipulating T regulatory cells in cancer immunotherapy. 2006 , 1, 589-597	3

749	Targeting tumor-related immunosuppression for cancer immunotherapy. 2006 , 6, 233-7	57
748	Enhancing photodynamic therapy of a metastatic mouse breast cancer by immune stimulation. 2006 ,	0
747	Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. 2006 , 16, 141	13
746	Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes. 2006 , 29, 398-406	23
745	Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. 2006 , 29, 416-24	96
744	Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. 2006 , 212, 28-50	966
743	The tumor-draining lymph node as an immune-privileged site. 2006 , 213, 146-58	190
742	The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. 2006 , 214, 229-38	204
741	Review article: immune suppression and colorectal cancer. 2006 , 24, 1163-77	69
740	Regulatory T cells, tumour immunity and immunotherapy. 2006 , 6, 295-307	1581
739	Immune regulation in tumor-bearing hosts. 2006 , 18, 214-9	44
738	Combined chemoimmunotherapy of solid tumours: improving vaccines?. 2006 , 58, 975-90	80
737	Regulating the immune response to tumours. 2006 , 58, 948-61	49
736	Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. 2006 , 11, 1513-24	34
735	Chaperone-rich cell lysates, immune activation and tumor vaccination. 2006 , 55, 329-38	36
734	Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. 2007 , 56, 48-59	158
733	Prospects for exosomes in immunotherapy of cancer. 2006 , 10, 376-88	125
732	Regulatory cells and human cancer. 2006 , 16, 98-105	69

731	Suppression of anti-cancer immunity by regulatory T cells: back to the future. 2006 , 16, 137-49	53
730	Lessons from ColeyB Toxin. 2006 , 15, 25-8	59
729	Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. 2006 , 118, 2790-5	35
728	Clinical Pharmacology of Cyclophosphamide and Ifosfamide. 2006 , 1, 55-84	71
727	IL-2 Receptor Targeted Immunomodulatory Biologics: The Past, Present, and Future. 2006 , 2, 187-208	0
726	The Diabetes Type 1 Locus Idd6 Modulates Activity of CD4+CD25+ Regulatory T-Cells. 2006 , 55, 186-192	10
725	Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. 2006 , 176, 6631-9	54
724	Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. 2006 , 5, 2592-9	44
723	Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. 2006 , 12, 878-87	336
722	Effect of CD4+CD25+ and CD4+CD25- T regulatory cells on the generation of cytolytic T cell response to a self but human tumor-associated epitope in vitro. 2006 , 176, 984-90	36
721	Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. 2006 , 20, 374-6	36
720	Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. 2006 , 12, 465-72	441
719	Dendritic cell derived-exosomes: biology and clinical implementations. 2006 , 80, 471-8	103
718	Current progress in the development of a cell-based vaccine for the immunotherapy of acute myeloid leukemia. 2006 , 5, 211-22	3
717	GM-CSF gene-modified cancer cell immunotherapies: of mice and men. 2006 , 25, 321-52	80
716	Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. 2006 , 177, 6603-12	155
715	Regulatory roles of NKT cells in the induction and maintenance of cyclophosphamide-induced tolerance. 2006 , 177, 8400-9	17
714	Recombinant adenovirus vaccines can successfully elicit CD8+ T cell immunity under conditions of extreme leukopenia. 2006 , 13, 270-9	8

713	Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. 2006 , 176, 2722-9	174
712	Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. 2006 , 66, 960-9	76
711	Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. 2007 , 13, 644-53	191
710	Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity. 2007 , 179, 7593-604	101
709	Immunotherapy of melanoma: a critical review of current concepts and future strategies. 2007 , 7, 345-58	41
708	Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. 2007 , 104, 12087-92	175
707	Design of new oxazaphosphorine anticancer drugs. 2007 , 13, 963-78	20
706	Chemotherapy enhances CD8(+) T cell-mediated antitumor immunity induced by vaccination with vaccinia virus. 2007 , 15, 1558-63	27
705	Regulatory T cells--the renaissance of the suppressor T cells. 2007 , 39, 322-34	19
704	The safety profile of cyclophosphamide in multiple sclerosis therapy. 2007 , 6, 183-90	51
703	Clinical utilization of chemokines to combat cancer: the double-edged sword. 2007 , 6, 267-83	38
702	Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. 2007 , 67, 792-801	492
701	Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. 2007 , 67, 802-11	102
700	Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. 2007 , 179, 2493-500	106
699	How regulatory CD25+CD4+ T cells impinge on tumor immunobiology: the differential response of tumors to therapies. 2007 , 179, 5659-68	28
698	Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics. 2007 , 3, 174-193	7
697	Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer. 2007 , 67, 1291-8	46
696	Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. 2007 , 67, 5929-39	79

695	Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. 2007 , 67, 7941-4	116
694	Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. 2007 , 13, 4487-94	70
693	Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy. 2007 , 30, 438-47	56
692	Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. 2007 , 30, 240-50	25
691	Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. 2007 , 30, 40-53	93
690	Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. 2007 , 25, 3485-91	31
689	Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. 2007 , 117, 2570-82	607
688	Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. 2007 , 13, 277-92	20
687	General Principles of Tumor Immunotherapy. 2007 ,	2
686	Review: cancer immunotherapy by exosome-based vaccines. 2007 , 22, 692-703	48
685	Advances in dendritic-cell-based therapeutic vaccines for cervical cancer. 2007 , 7, 1473-86	27
684	Current immunotherapeutic strategies in colon cancer. 2007 , 16, 873-900, x	10
683	T-Regulatory Cell Manipulation in Tumor Immunotherapy. 2007 , 189-204	
682	Immunotherapy and Cancer Therapeutics: Why Partner?. 2007 , 207-233	4
681	Modification of the tumor microenvironment to enhance immunity. 2007 , 12, 3576-600	39
680	Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. 2008 , 122, 1794-802	71
679	Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity. <i>European Journal of Immunology</i> , 2007 , 37, 758-67	6.1 24
678	Cellular and molecular events associated with the antitumor response induced by the cytosine deaminase/5-fluorocytosine suicide gene therapy system in a rat liver metastasis model. 2007 , 14, 858-66	9

677	Reply: Forkhead box P3-positive regulatory T cells in immune surveillance and cancer. 2007 , 97, 1017-1018	1
676	Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. 2007 , 122, 615-22	45
675	Regulatory T cells and tumour immunity - observations in mice and men. 2008 , 123, 157-63	86
674	Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. 2007 , 150, 523-30	96
673	Virus-based immunotherapy of cancer: what do we know and where are we going?. 2007 , 115, 1177-93	4
672	Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. 2007 , 12, 192-9	55
671	T regulatory cells: aid or hindrance in the clearance of disease?. 2007 , 11, 1291-325	11
670	IFN-alpha and novel strategies of combination therapy for cancer. 2007 , 1112, 256-68	19
669	Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. 2007 , 85, 1069-76	58
668	Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. 2007 , 56, 641-8	944
667	Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. 2007 , 56, 1597-604	122
666	Cyclophosphamide promotes pulmonary metastasis on mouse lung adenocarcinoma. 2008 , 25, 855-64	22
665	Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. 2008 , 57, 977-86	71
664	Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. 2008 , 57, 1579-87	120
663	Gammadelta T lymphocytes: a new type of regulatory T cells suppressing murine 2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced colitis. 2008 , 23, 909-20	18
662	Oncolytic virotherapy as a personalized cancer vaccine. 2008 , 123, 493-9	23
661	The immune system--is it relevant to cancer development, progression and treatment?. 2008 , 20, 101-12	74
660	Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. 2008 , 224, 141-65	182

659	Increased number of CD25 FoxP3 regulatory T cells in oral squamous cell carcinomas detected by chromogenic immunohistochemical double staining. 2008 , 37, 485-9	29
658	Apoptosis as a mechanism of T-regulatory cell homeostasis and suppression. 2008 , 86, 650-8	52
657	Immunological aspects of cancer chemotherapy. 2008 , 8, 59-73	1072
656	The kiss of death by dendritic cells to cancer cells. 2008 , 15, 58-69	54
655	Tumor stress, cell death and the ensuing immune response. 2008 , 15, 21-8	68
654	Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. 2008 , 128, 1506-16	68
653	Special regulatory T-cell review: A rose by any other name: from suppressor T cells to Tregs, approbation to unbridled enthusiasm. 2008 , 123, 20-7	51
652	Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. 2008 , 129, 219-29	136
651	Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. 2008 , 1, 228-39	58
650	Comparative methodologies of regulatory T cell depletion in a murine melanoma model. 2008 , 333, 167-79	77
649	Dendritic cells in cancer immunotherapy. 2008 , 99, 363-407	55
648	Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine. 2008 , 7, 995-1003	11
647	Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. 2008 , 14, 5220-7	430
646	Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. 2008 , 14, 259-69	142
645	Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?. 2008 , 14, 5242-9	91
644	Combining immunotherapy with classical anticancer therapy. 2008 , 19 Suppl 7, vii252-5	1
643	Oncolytic viruses: a novel form of immunotherapy. 2008 , 8, 1581-8	129
642	Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics. 2008 , 9, 2639-60	6

641	Outlining the Gap Between Preclinical Models and Clinical Situation. 2008 , 31-54	
640	Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor. 2008 , 14, 2833-40	11
639	Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. 2008 , 105, 5495-500	162
638	Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. 2008 , 181, 6955-63	130
637	Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity. 2008 , 68, 7264-9	50
636	CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. 2008 , 105, 2999-3004	106
635	Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression. 2008 , 83, 1049-59	18
634	Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. 2008 , 14, 5166-72	227
633	The anticancer immune response: indispensable for therapeutic success?. 2008 , 118, 1991-2001	450
632	Exosomes for the treatment of human malignancies. 2008 , 40, 82-8	24
631	T-regulatory cells in tumour-specific vaccination strategies. 2008 , 8, 1365-79	16
630	Anticancer immunotherapy in combination with proapoptotic therapy. 2008 , 8, 666-75	15
629	Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy. 2008 , 8, 385-95	17
628	Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. 2008 , 111, 5359-70	99
627	Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. 2008 , 28, 109-26	126
626	Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer. 2008 , 2, 555-61	2
625	The role of T-regulatory cells in pregnancy and cancer. 2008 , 13, 2275-89	29
624	CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. 2008 , 118, 3751-61	52

623	Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. 2009 , 35, 569-81	37
622	The role of regulatory T cells in cancer. 2009 , 9, 209-35	69
621	Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. 2009 , 14, 1761-70	50
620	FOXP3 and its role in the immune system. 2009 , 665, 17-29	41
619	Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. 2009 , 69, 6978-86	104
618	Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma. 2009 , 182, 1667-73	26
617	T-regulatory cell modulation: the future of cancer immunotherapy?. 2009 , 100, 1697-703	77
616	Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers. 2009 , 4, 587-603	6
615	Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. 2009 , 183, 137-44	184
614	Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. 2009 , 15, 6167-76	24
613	Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. 2009 , 15, 561-9	56
612	OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. 2009 , 206, 1103-16	174
611	Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. 2009 , 15, 6881-90	36
610	Cellular immunotherapy for ovarian cancer. 2009 , 9, 677-88	25
609	Anti-4-1BB scFv immunogene therapy and low dose cyclophosphamide exhibit a synergistic antitumor effect in established murine lung tumors. 2009 , 8, 707-13	5
608	A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. 2009 ,	2
607	Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. 2009 , 18, 1001-11	161
606	The Yin and Yang of CD4(+) regulatory T cells in autoimmunity and cancer. 2009 , 16, 4626-31	22

605	Treatment of lymphoma with adoptively transferred T cells. 2009 , 9, 1407-25		13
604	Multipeptide vaccination in cancer patients. 2009 , 9, 1043-55		48
603	Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. 2009 , 15, 2166-73		111
602	Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. 2009 , 27, 5911-8		178
601	Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses. 2009 , 15, 2756-66		9
600	Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation. 2009 , 330, 596-601		33
599	A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice. 2009 , 15, 7256-65		29
598	Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy. 2009 , 8, 469-78		40
597	Autoimmune spread to myelin is associated with experimental autoimmune encephalomyelitis induced by a neuronal protein, beta-synuclein. 2009 , 208, 19-29		7
596	CD 4+ T cells in the pathobiology of neurodegenerative disorders. 2009 , 211, 3-15		44
595	Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. 2009 , 124, 130-9		89
594	Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy. 2009 , 75, 175-88		66
593	Treg suppress CTL responses upon immunization with HSP gp96. <i>European Journal of Immunology</i> , 2009 , 39, 3110-20	6.1	47
592	VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. <i>European Journal of Immunology</i> , 2010 , 40, 197-203	6.1	84
591	Anti-tumor immune response in ovarian cancer: clinical implications, prognostic significance and potential for novel treatment strategies. 2009 , 3, 173-186		
590	Refractory chronic immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia. 2009 , 90, 483-485		9
589	Immunotherapy: from basic research to clinical applications. 2009 , 58, 1129-36		1
588	Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. 2009 , 58, 441-7		65

587	Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. 2009 , 58, 317-24	105
586	Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. 2009 , 58, 615-28	77
585	The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. 2009 , 58, 1033-45	309
584	Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. 2009 , 58, 1219-28	99
583	Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. 2009 , 58, 1627-34	174
582	Combined therapy with cyclophosphamide and DNA preparation inhibits the tumor growth in mice. 2009 , 7, 12	11
581	Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host. 2009 , 6, 3-13	67
580	High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome. 2009 , 16, 338-50	22
579	T cell-mediated immunoregulation in the gastrointestinal tract. 2009 , 64, 505-19	64
578	Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. 2009 , 74, 1-10	12
577	Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers. 2009 , 1174, 41-50	12
576	Immunotherapy of diffuse gliomas: biological background, current status and future developments. 2009 , 19, 674-93	73
575	CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma. 2009 , 61, 275-82	11
574	Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. 2009 , 69, 6987-94	93
573	End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+ T-cells. 2009 , 24, 1969-78	76
572	Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine. 2009 , 27, 2230-9	11
571	Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects. 2009 , 9, 1063-70	14
570	Regulatory T cells and ST2 signaling control diabetes induction with multiple low doses of streptozotocin. 2009 , 47, 28-36	45

569	Pharmacologic and chemical adjuvants in tumor virotherapy. 2009 , 109, 3125-40	41
568	Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. 2009 , 7, 18	21
567	Dendritic Cells in Cancer. 2009 ,	1
566	Enhancing the efficacy of cancer vaccines in urologic oncology: new directions. 2009 , 6, 540-9	24
565	Role of Regulatory Subsets During Aging. 2009 , 343-377	1
564	Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice. 2009 , 61, 550-7	36
563	Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma. 2009 , 32, 333-40	12
562	Regulatory T cells actively infiltrate metastatic brain tumors. 2009 , 34, 1533-40	26
561	Pre-treatment with cyclophosphamide or OX40 (CD134) costimulation targeting regulatory T cell function enhances the anti-tumor immune effect of adoptively transferred CD8+ T cells from wild-type mice. 2009 , 2, 615-20	10
560	Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. 2009 , 9, 673-82	24
559	Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. 2009 , 32, 92-9	44
558	Targeting indoleamine 2,3-dioxygenase (IDO) to counteract tumour-induced immune dysfunction: from biochemistry to clinical development. 2009 , 9, 151-77	6
557	Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge. 2010 , 6, 229-242	
556	Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients. 2010 , 33, 723-34	16
555	Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. 2010 , 33, 435-41	173
554	Chemoimmunotherapy. 2010 , 16, 295-303	87
553	Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. 2010 , 33, 211-8	109
552	Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. 2010 , 115, 4384-92	90

551	Cyclophosphamide, DCs, and Tregs. 2010 , 115, 4322-4	2
550	Immune responses in hepatocellular carcinoma. 2010 , 28, 150-4	35
549	Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. 2010 , 59, 137-48	83
548	Killer dendritic cells and their potential for cancer immunotherapy. 2010 , 59, 1-11	37
547	Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma. 2010 , 59, 769-77	46
546	Regulatory T cell as a target for cancer therapy. 2010 , 58, 179-90	25
545	Surgically unresectable regional melanoma metastases in a patient with renal failure and peripheral vascular disease: are there safe and potentially effective treatments?. 2010 , 37, 303-13	
544	Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma. 2010 , 11, 54	6
543	Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo. 2010 , 261, 134-43	50
542	Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization. 2010 , 262, 150-61	27
541	Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. 2010 , 263, 79-87	100
540	CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. 2010 , 136, 21-9	31
539	Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. 2010 , 14, 2748-59	43
538	Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. 2010 , 32, 946-58	42
537	A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation. 2010 , 8, 7	19
536	Mifepristone (RU486) restores humoral and T cell-mediated immune response in endotoxin immunosuppressed mice. 2010 , 162, 568-77	23
535	Harnessing the immune response to treat cancer. 2010 , 29, 6301-13	65
534	Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. 2010 , 103, 52-60	58

533	FOXP3+ regulatory T cells in the human immune system. 2010 , 10, 490-500	1713
532	Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. 2010 , 1194, 169-78	50
531	Les lymphocytes T r�gulateurs et les lymphocytes Th17 : fonctions physiologiques et pathologiques. 2010 , 2010, 31-40	
530	Regulatory T Cells. 2010 , 87-107	
529	Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. 2010 , 120, 457-71	651
528	Immunotoxicology of Pesticides and Chemotherapies. 2010 , 467-487	3
527	The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. 2010 , 16, 1272-80	85
526	Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. 2010 , 9, 996-1006	92
525	Immunotherapy of hepatocellular carcinoma. 2010 , 4, 345-53	14
524	Manipulation of regulatory T-cell function by immunomodulators: a boon or a curse?. 2010 , 117, 253-62	11
523	Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma. 2010 , 185, 956-66	25
522	Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. 2010 , 17, 143-53	56
521	Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse model. 2010 , 3, 1265-76	25
520	Tumor antigen cross-presentation and the dendritic cell: where it all begins?. 2010 , 2010, 539519	42
519	Overview of cellular immunotherapy for patients with glioblastoma. 2010 , 2010,	62
518	Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. 2010 , 2010, 791603	37
517	Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity. 2010 , 2010, 798467	29
516	Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist. 2010 , 42, 407-19	26

515	Redirecting the immune response: role of adoptive T cell therapy. 2010 , 21, 533-41	8
514	Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. 2010 , 184, 1737-47	54
513	Biology and clinical observations of regulatory T cells in cancer immunology. 2011 , 344, 61-95	27
512	Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses. 2010 , 184, 6833-42	80
511	Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. 2010 , 16, 3035-43	84
510	Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis. 2010 , 2010, 504979	17
509	Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience. 2010 , 2010, 692097	20
508	T regulatory cells in cancer: recent advances and therapeutic potential. 2010 , 10, 1573-86	85
507	Personalized dendritic cell-based tumor immunotherapy. 2010 , 2, 57-68	51
506	Enhancement of antitumor immunity by low-dose total body irradiation is associated with selectively decreasing the proportion and number of T regulatory cells. 2010 , 7, 157-62	54
505	Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. 2010 , 10, 19-28	26
504	5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. 2010 , 70, 3052-61	884
503	Interactions Between NK Cells and Regulatory T Cells. 2010 , 329-343	1
502	Metronomic chemotherapy: new rationale for new directions. 2010 , 7, 455-65	457
501	Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1. 2010 , 9, 617-29	20
500	High-dose cyclophosphamide-mediated anti-tumor effects by the superior expansion of CD44(high) cells after their selective depletion. 2010 , 215, 182-93	7
499	Interleukin-21 restrains tumor growth and induces a substantial increase in the number of circulating tumor-specific T cells in a murine model of malignant melanoma. 2010 , 49, 80-8	8
498	Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes. 2010 , 16, 1629-48	30

497	The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy. 2010 , 59, 279-91	50
496	A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. 2010 , 10, 209	138
495	Human FOXP3 and cancer. 2010 , 29, 4121-9	100
494	Immunogenicity and immunomodulatory properties of HPMA-based polymers. 2010 , 62, 184-91	69
493	Forkhead Transcription Factors. 2010 ,	4
492	From Molecular to Modular Tumor Therapy. 2010 ,	5
491	Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy. 2010 , 107, 1-37	18
490	Natural Killer Cells. 2010 ,	3
489	Photodynamic therapy for cancer and activation of immune response. 2010 ,	1
488	Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. 2010 , 70, 4850-8	153
487	Combination approaches to potentiate immune response after photodynamic therapy for cancer. 2011 , 10, 792-801	44
486	Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. 2011 , 71, 768-78	240
485	Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide. 2011 , 71, 3528-39	57
484	Safety of glucocorticoids in cancer patients treated with oncolytic adenoviruses. 2011 , 8, 93-103	4
483	Experimental and Applied Immunotherapy. 2011 ,	
482	Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12. 2011 , 5, 242-55	25
481	High-Grade Gliomas: Dendritic Cell Therapy. 2011 , 313-333	
480	Tumors of the Central Nervous System, Volume 2. 2011 ,	1

479	Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma. 2011 , 30, 24	18
478	Immunotherapy in prostate cancer: emerging strategies against a formidable foe. 2011 , 29, 6485-97	16
477	Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. 2011 , 25, 920-6	82
476	How to improve the immunogenicity of chemotherapy and radiotherapy. 2011 , 30, 71-82	66
475	Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN- γ -dependent mechanism. 2011 , 187, 6310-7	24
474	Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. 2011 , 13, R126	261
473	Immunotherapy with Dendritic Cells and Newcastle Disease Virus in Glioblastoma Multiforme. 2011 , ,	
472	Novel therapeutic strategies for targeting liver cancer stem cells. 2011 , 7, 517-35	117
471	The potential role of functional inhibition of T regulatory cells by anti-TGF β antibody in photodynamic therapy of renal cancer. 2011 , ,	
470	Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. 2011 , 117, 1555-64	16
469	Oral ingestion of Lentinula edodes mycelia extract inhibits B16 melanoma growth via mitigation of regulatory T cell-mediated immunosuppression. 2011 , 102, 516-21	23
468	Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. 2011 , 153, 568-81	70
467	Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. 2011 , 11, 505	24
466	Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo. 2011 , 271, 67-72	41
465	Intravenous immunoglobulins exposed to heme (heme IVIG) are more efficient than IVIG in attenuating autoimmune diabetes. 2011 , 138, 162-71	19
464	Stimulation of anti-tumor immunity by photodynamic therapy. 2011 , 7, 75-91	162
463	Immunomodulating effect of cyclophosphamide on cytotoxic activity of rat and mouse splenocytes. 2011 , 5, 586-594	
462	Lymphadenectomy exacerbates tumor growth while lymphadenectomy plus the adoptive transfer of autologous cytotoxic cells and low-dose cyclophosphamide induces regression of an established murine fibrosarcoma. 2011 , 60, 389-99	4

461	Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. 2011 , 60, 909-18		247
460	Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. 2011 , 33, 369-83		217
459	Contribution of the immune system to the chemotherapeutic response. 2011 , 33, 353-67		29
458	Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. 2011 , 34, 97-106		68
457	Immunosuppressive tumor microenvironment in cervical cancer patients. 2011 , 4, 361-75		77
456	Metronomic therapy concepts in the management of adrenocortical carcinoma. 2011 , 2, 378-84		12
455	Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. 2011 , 9, 139		42
454	Combination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer. 2011 , 9, 140		9
453	Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. <i>European Journal of Immunology</i> , 2011 , 41, 2217-28	6.1	59
452	Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. <i>European Journal of Immunology</i> , 2011 , 41, 2977-86	6.1	117
451	Neem leaf glycoprotein inhibits CD4+CD25+Foxp3+ Tregs to restrict murine tumor growth. 2011 , 3, 949-69		22
450	Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. 2011 , 19, 1737-46		129
449	Skewing the balance of regulatory T-cells and T-helper 17 cells in breast cancer patients. 2011 , 39, 691-701		17
448	Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease. 2011 , 8, 289-95		5
447	A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. 2011 , 11, 1409-18		20
446	Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. 2011 , 186, 807-15		77
445	In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. 2011 , 71, 2871-81		70
444	Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multi-peptide melanoma vaccine. 2011 , 29, 2924-32		88

443	Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. 2011 , 17, 841-8	68
442	Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation. 2011 , 187, 4109-18	8
441	From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. 2011 , 10, 743-53	15
440	Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapy. 2011 , 2011, 269519	29
439	The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. 2011 , 2011, 430394	62
438	Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. 2012 , 2012, 753407	24
437	Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. 2012 , 2012, 473712	64
436	Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities. 2012 , 3, 103	5
435	Targeting and utilizing primary tumors as live vaccines: changing strategies. 2012 , 9, 20-6	5
434	Arsenic trioxide exerts antitumor activity through regulatory T cell depletion mediated by oxidative stress in a murine model of colon cancer. 2012 , 189, 5171-7	49
433	Immunomodulation and anti-inflammatory roles of polyphenols as anticancer agents. 2012 , 12, 852-73	59
432	ChemImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents. 2012 , 19, 1792-803	52
431	Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. 2012 , 18, 850-7	58
430	B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. 2012 , 189, 2338-47	39
429	Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. 2012 , 18, 6668-78	114
428	Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. 2012 , 18, 2943-53	75
427	Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. 2012 , 72, 3439-44	181
426	Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model. 2012 , 35, 607-14	17

425	Bugs and drugs: oncolytic virotherapy in combination with chemotherapy. 2012 , 13, 1817-33	52
424	Can targeted therapy be successful without metronomic scheduling?. 2012 , 12, 1639-42	6
423	Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. 2012 , 10, 1505-12	11
422	Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine. 2012 , 13, 1773-85	4
421	[Immunotherapy: an emerging strategies against prostate castration resistant cancer]. 2012 , 99 Suppl 1, S57-65	
420	Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity. 2012 , 249, 176-94	73
419	Combining a peptide vaccine with oral ingestion of Lentinula edodes mycelia extract enhances anti-tumor activity in B16 melanoma-bearing mice. 2012 , 61, 2143-52	14
418	Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. 2012 , 2, 628-39	152
417	Tumour-infiltrating T-cell subpopulations in glioblastomas. 2012 , 26, 21-7	42
416	Myeloid-derived suppressor cells from tumor-bearing mice impair TGF- β -induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. 2012 , 92, 987-97	60
415	Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells. 2012 , 73, 207-13	23
414	IFN- γ -producing T cells contribute to the increase of myeloid derived suppressor cells in tumor-bearing mice after cyclophosphamide treatment. 2012 , 12, 425-32	10
413	Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide. 2012 , 276, 67-74	25
412	Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy. 2012 , 4, 581-600	10
411	Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma. 2012 , 170, 291-9	12
410	Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity. 2012 , 47, 1112-7	14
409	Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy. 2012 , 6, 1-14	37
408	Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package. 2012 , 79, 1617-22	21

407	Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies. 2012 , 107, 1107-15	47
406	Primary Liver Cancer. 2012 ,	3
405	Innate Immune Regulation and Cancer Immunotherapy. 2012 ,	3
404	Y27, a novel derivative of 4-hydroxyquinoline-3-formamide, prevents the development of murine systemic lupus erythematosus-like diseases in MRL/lpr autoimmune mice and BDF1 hybrid mice. 2012 , 14, R235	7
403	Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. 2012 , 7, e47077	85
402	Immunosuppressive treatments in acute myocardial infarction and stroke. 2012 , 13, 59-67	6
401	Antitumor effect of a polypeptide fraction from <i>Arca subcrenata</i> in vitro and in vivo. 2012 , 10, 2782-94	18
400	Cellular Immunotherapy Using Dendritic Cells Against Multiple Myeloma. 2012 ,	
399	The Influence of Cyclophosphamide on Immune Function of Murine Macrophages. 2012 ,	
398	Regulatory Cells and Multiple Myeloma. 2012 ,	1
397	Combining immunotherapy and targeted therapies in cancer treatment. 2012 , 12, 237-51	1007
396	Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. 2012 , 119, 4133-41	442
395	The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. 2012 , 131, 8-17	30
394	Potential of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. 2012 , 131, E670-80	66
393	Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. 2012 , 109, 4592-7	127
392	Role of myeloid-derived suppressor cells in tumor immunotherapy. 2012 , 4, 43-57	27
391	T-regulatory cells: key players in tumor immune escape and angiogenesis. 2012 , 72, 2162-71	509
390	Regulatory T cell: a protection for tumour cells. 2012 , 16, 425-36	47

389	Regulatory T cells in the central nervous system. 2012 , 248, 156-69	89
388	Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses. 2012 , 22, 50-9	26
387	Immunotherapy for treating metastatic colorectal cancer. 2012 , 21, 67-77	9
386	A reduction of recipient regulatory T cells by cyclophosphamide contributes to an anti-tumor effect of nonmyeloablative allogeneic stem cell transplantation in mice. 2012 , 130, 365-76	12
385	Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. 2012 , 61, 353-62	166
384	Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. 2012 , 61, 109-17	32
383	Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. 2013 , 11, 16	39
382	Cancer Immunotherapy. 2013 ,	1
381	Preexisting antitumor immunity augments the antitumor effects of chemotherapy. 2013 , 62, 1061-71	11
380	Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. 2013 , 62, 897-908	28
379	Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response. 2013 , 62, 455-69	10
378	Endocrine disruptors found in food contaminants enhance allergic sensitization through an oxidative stress that promotes the development of allergic airway inflammation. 2013 , 273, 10-8	8
377	Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. 2013 , 5, 211ra157	216
376	The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. 2013 , 342, 971-6	1128
375	Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. 2013 , 342, 976-9	379
374	Functional switching and stability of regulatory T cells. 2013 , 75, 1891-911	5
373	Oncolytic viruses as therapeutic cancer vaccines. 2013 , 12, 103	206
372	ENTPD1/CD39 is a promising therapeutic target in oncology. 2013 , 32, 1743-51	133

371	Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen. 2013 , 109, 2167-74	39
370	Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. 2013 , 62, 171-82	54
369	Chemoimmunotherapy: reengineering tumor immunity. 2013 , 62, 203-16	162
368	Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. 2013 , 6, 511-9	29
367	Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. 2013 , 19, 1368-73	24
366	High-dose cyclophosphamide used to treat aplastic anemia in a patient with respiratory and food allergies has a prolonged effect on serum IgE levels. 2013 , 132, 237-9	
365	Suppression, subversion and escape: the role of regulatory T cells in cancer progression. 2013 , 171, 36-45	147
364	Inducers of immunogenic cancer cell death. 2013 , 24, 319-33	154
363	Combining Vaccines with Therapies that Render Tumor Cells more Susceptible to Immune Mediated Killing. 2013 , 621-642	
362	Peripheral Treg count and it β determinants in unsensitized and sensitized chronic kidney disease patients. 2013 , 45, 1647-52	5
361	Cell Death Signaling in Cancer Biology and Treatment. 2013 ,	1
360	The Tumor Immunoenvironment. 2013 ,	3
359	Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. 2013 , 62, 383-91	81
358	Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. 2013 , 132, 2471-8	80
357	Immune ambivalence: The schizophrenic bleomycin. 2013 , 2, e25737	3
356	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. 2013 , 12, 597-615	49
355	Metronomic therapy: chemotherapy revisited. 2013 , 50, 142-8	15
354	Immunotherapy and immune evasion in prostate cancer. 2013 , 5, 569-90	17

353	Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. 2013 , 133, 499-508	58
352	How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development. 2013 , 4, 292	34
351	Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. 2013 , 133, 98-107	116
350	Cytosine arabinoside promotes cytotoxic effect of T cells on leukemia cells mediated by bispecific antibody. 2013 , 24, 751-60	5
349	Profound impairment of adaptive immune responses by alkylating chemotherapy. 2013 , 190, 6259-68	54
348	Characterization of a cyclophosphamide-induced murine model of immunosuppression to study <i>Acinetobacter baumannii</i> pathogenesis. 2013 , 62, 1747-1754	24
347	Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy. 2013 , 19, 4249-61	59
346	Combined use of cyclophosphamide and Chalone 19-peptide in experimental breast cancer. 2013 , 6, 861-7	1
345	Regulatory T cells in allogeneic stem cell transplantation. 2013 , 2013, 608951	22
344	Zonal difference and prognostic significance of foxp3 regulatory T cell infiltration in breast cancer. 2014 , 17, 8-17	22
343	[Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets]. 2014 , 101, 605-7	10
342	[Tumor microenvironment: regulatory cells and immunosuppressive cytokines]. 2014 , 30, 429-35	4
341	Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. 2014 , 3, 151-65	9
340	Immunostimulatory Effects of Triggering TLR3 Signaling Pathway [Implication for Cancer Immunotherapy]. 2014 ,	
339	Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer. 2014 , 4, 145	43
338	Metronomic Chemotherapy. 2014 ,	2
337	Monitoring the frequency and function of regulatory T cells and summary of the approaches currently used to inhibit regulatory T cells in cancer patients. 2014 , 1139, 201-21	2
336	Nano-Oncologicals. 2014 ,	4

335	Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. 2014 , 6, 80	37
334	Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial. 2014 , 37, 26-35	34
333	Preclinical Activity of Metronomic Regimens with Alkylating Agents and Antimetabolites. 2014 , 53-67	
332	Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors. 2014 , 10, 1273-1285	125
331	Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells. 2014 , 43, 517-34	9
330	Increase of peripheral T regulatory cells during remission induction with cyclophosphamide in active systemic lupus erythematosus. 2014 , 17, 790-5	11
329	Adoptive immunotherapy of metastatic breast cancer: present and future. 2014 , 33, 309-20	16
328	Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. 2014 , 74, 104-18	247
327	Chemotherapeutic targeting of cancer-induced immunosuppressive cells. 2014 , 74, 2663-8	106
326	Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. 2014 , 110, 459-68	115
325	Induction of Bcl-xL-specific cytotoxic T lymphocytes in mice. 2014 , 80, 111-20	1
324	Camptothecin prodrug block copolymer micelles with high drug loading and target specificity. 2014 , 5, 5320-5329	30
323	Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. 2014 , 2, 616-31	322
322	Harnessing the intestinal microbiome for optimal therapeutic immunomodulation. 2014 , 74, 4217-21	32
321	Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. 2014 , 12, 245	9
320	Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2K(d) -specific CD8+ T cells. 2014 , 134, 2841-52	6
319	mTOR signaling inhibition modulates macrophage/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia. 2014 , 192, 6009-19	116
318	Critical stoichiometric ratio of CD4(+) 'CD25(+) 'FoxP3(+) regulatory T cells and CD4(+) 'CD25(-) responder T cells influence immunosuppression in patients with B-cell acute lymphoblastic leukaemia. 2014 , 142, 124-39	24

317	Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer. 2014 , 50, 457-67	14
316	Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. 2014 , 124, 2131-41	111
315	Immunoenhancing properties of the anti-tumor effects of adoptively transferred T cells with chemotherapeutic cyclophosphamide by co-administration of bone marrow cells. 2015 , 72, 96-103	2
314	A distinct chemokine axis does not account for enrichment of Foxp3(+) CD4(+) T cells in carcinogen-induced fibrosarcomas. 2015 , 145, 94-104	5
313	Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer. 2015 , 5, 15659	93
312	Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. 2015 , 5, 15179	488
311	Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastoma. 2015 , 3, 24	10
310	Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. 2015 , 6, 516	51
309	Neutropenia exacerbates infection by Acinetobacter baumannii clinical isolates in a murine wound model. 2015 , 6, 1134	17
308	Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. 2015 , 64, 1305-14	23
307	Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. 2015 , 28, 690-714	828
306	Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer. 2015 , 43, 180-7	22
305	Metronomic chemotherapy from rationale to clinical studies: a dream or reality?. 2015 , 95, 46-61	53
304	A model for effects of adaptive immunity on tumor response to chemotherapy and chemoimmunotherapy. 2015 , 380, 569-84	14
303	Antitumor activity of mHSP65-TTL enhanced by administration of low dose cyclophosphamide in pancreatic cancer-bearing mice. 2015 , 27, 95-103	3
302	High-dose cyclophosphamide induces specific tumor immunity with concomitant recruitment of LAMP1/CD107a-expressing CD4-positive T cells into tumor sites. 2015 , 366, 93-9	8
301	Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. 2015 , 7, 499-512	16
300	Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy. 2015 , 195, 726-35	18

299	Cancer vaccines. 2015 , 350, h988	156
298	Renal cancer treatment with recipient lymphocyte infusion enhanced the antitumor effect of nonmyeloablative allogeneic stem cell transplantation. 2015 , 32, 131-9	4
297	Immunomodulatory therapy in refractory/recurrent ovarian cancer. 2015 , 54, 143-9	2
296	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. 2015 , 17, 18	17
295	Immunosurveillance and therapy of multiple myeloma are CD226 dependent. 2015 , 125, 2077-89	69
294	Strategies to potentiate immune response after photodynamic therapy. 2015 ,	
293	Combination effect of regulatory T-cell depletion and ionizing radiation in mouse models of lung and colon cancer. 2015 , 92, 390-8	32
292	Macrophages play an essential role in antigen-specific immune suppression mediated by T CD8+ cell-derived exosomes. 2015 , 146, 23-32	38
291	Immune-mediated mechanisms influencing the efficacy of anticancer therapies. 2015 , 36, 198-216	93
290	Relevance of tumor-infiltrating lymphocytes in breast cancer. 2015 , 13, 202	131
289	Checkpoint blockade in combination with cancer vaccines. 2015 , 33, 7377-7385	31
288	Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. 2015 , 17 Suppl 7, vii32-vii40	15
287	Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice. 2015 , 102, 327-34	16
286	Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?. 2015 , 11, 2645-2654	26
285	Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma. 2015 , 369, 242-9	27
284	Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- κ B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. 2015 , 75, 5034-45	318
283	Targeting the bone marrow microenvironment in multiple myeloma. 2015 , 263, 160-72	223
282	Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. 2015 , 32, 443	13

281	Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state. 2015 , 106, 9-17	9
280	Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy. 2015 , 8, 57-64	20
279	Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease. 2015 , 21, 604-11	81
278	Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy. 2015 , 144, 186-96	31
277	Immunotherapy in Colorectal Cancer. 2016 ,	
276	Combining Immunotherapies with Standard Therapies in the Treatment of Cancer. 2016 , 569-580	
275	Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. 2016 , 5, 1-13	48
274	Immunotherapy with methyl gallate, an inhibitor of Treg cell migration, enhances the anti-cancer effect of cisplatin therapy. 2016 , 20, 261-8	8
273	Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade. 2016 , 2016, 8121985	19
272	Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. 2016 , 4,	272
271	Vaccines and Their Role in CD8 T Cell-Mediated Antitumor Immunity. 2016 , 534-541	
270	Immune Checkpoint Therapy in Head and Neck Cancers. 2016 , 22, 108-16	10
269	Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. 2016 , 128, 2297-2306	37
268	Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas. 2016 , 16, 914	13
267	Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update. 2016 , 8, 1335-1346	6
266	Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. 2016 , 27, 1482-92	335
265	Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. 2016 , 65, 715-25	47
264	Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed. 2016 , 4, 377-82	32

263	Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. 2016 , 22, 4827-4836	20
262	Targeting the Bone Marrow Microenvironment. 2016 , 169, 63-102	9
261	Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy. 2016 , 11, 2699-2709	15
260	Associations of Selected Cytokines Levels in Organ Transplant Recipients Without and With Malignant Skin Neoplasms. 2016 , 48, 1654-9	2
259	Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy. 2016 ,	3
258	Immunogenic Apoptotic Cell Death and Anticancer Immunity. 2016 , 930, 133-49	60
257	Effect of administration timing of postchemotherapy granulocyte colony-stimulating factor on host-immune cell recovery and CD8 T-cell response. 2016 , 13, 784-792	4
256	DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer. 2016 , 65, 1061-73	28
255	Immunological Mechanisms Underneath the Efficacy of Cancer Therapy. 2016 , 4, 895-902	93
254	Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. 2016 , 1-39	
253	Combinatorial prospects of nano-targeted chemoimmunotherapy. 2016 , 83, 308-20	85
252	The influence of gut microbiota on drug metabolism and toxicity. 2016 , 12, 31-40	123
251	Low dose cyclophosphamide: Mechanisms of T cell modulation. 2016 , 42, 3-9	81
250	CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model. 2016 , 373, 88-96	23
249	Targeting inhibition of Foxp3 by a CD28 2PFluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy. 2016 , 91, 73-80	37
248	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. 2016 , 44, 343-54	518
247	Local Hyperthermia Treatment of Tumors Induces CD8+ T Cell-Mediated Resistance Against Distal and Secondary Tumors. 2016 , 309-347	3
246	A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice. 2016 , 14, 58	15

245	A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. 2016 , 65, 151-60	48
244	Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. 2016 , 28, 64-72	41
243	A MATHEMATICAL MODEL OF PANCREATIC CANCER WITH TWO KINDS OF TREATMENTS. 2017 , 25, 83-104	5
242	Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF- β II and NKG2D. 2017 , 66, 537-548	38
241	The microbiome in anti-cancer therapy. 2017 , 32, 74-81	47
240	Effects of combined epidural and general anesthesia on intraoperative hemodynamic responses, postoperative cellular immunity, and prognosis in patients with gallbladder cancer: A randomized controlled trial. 2017 , 96, e6137	15
239	CAR T-cell therapy: Balance of efficacy and safety. 2017 , 51, 237-250	4
238	Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer. 2017 , 161, 421-433	1
237	Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. 2017 , 400, 243-251	18
236	Regulatory T cells in cancer immunotherapy. 2017 , 27, 109-118	698
235	Immunological effects of everolimus in patients with metastatic renal cell cancer. 2017 , 30, 341-352	17
234	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. 2017 , 1868, 527-537	29
233	Probiotic species in the modulation of the anticancer immune response. 2017 , 46, 182-190	34
232	Development of Orthotopic and Spontaneous Metastatic Human Tumor Xenograft Models for Experimental Therapeutics. 2017 , 161-182	
231	Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models. 2017 , 108, 1974-1984	27
230	Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells. 2017 , 23, 1910-1917	27
229	Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. 2017 , 34, 308-319	10
228	Maintenance of memory CD8 T cells: Divided over division. <i>European Journal of Immunology</i> , 2017 , 47, 1875-1879	6.1 5

227	Immunomodulatory mechanism of Bushen Huoxue Recipe alleviates cyclophosphamide-induced diminished ovarian reserve in mouse model. 2017 , 208, 44-56	24
226	The importance of correctly timing cancer immunotherapy. 2017 , 17, 87-103	20
225	Metronomic chemotherapy and nanocarrier platforms. 2017 , 400, 232-242	9
224	Synergistic antitumor efficacy of antibacterial helvolic acid from <i>Cordyceps taii</i> and cyclophosphamide in a tumor mouse model. 2017 , 242, 214-222	13
223	Multiple Myeloma and the Immune Microenvironment. 2017 , 17, 806-818	35
222	The Role of Regulatory T Cells and Indoleamine-2,3-dioxygenase in Brain Tumor Immunosuppression. 2017 , 33-61	2
221	The Different Functional Distribution of "Not Effector" T Cells (Treg/Tnull) in Colorectal Cancer. 2017 , 8, 1900	27
220	Update on immune checkpoint inhibitors in gynecological cancers. 2017 , 28, e20	45
219	A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. 2017 , 17, 684	71
218	Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. 2017 , 8, 8890-8899	37
217	Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key. 2017 , 8, 437-446	15
216	T-cell modulation by cyclophosphamide for tumour therapy. 2018 , 154, 62-68	28
215	Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients. 2018 , 101, 68-77	11
214	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. 2018 , 7, e1433982	23
213	Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin. 2018 , 7, e1439305	5
212	Immunotherapy using regulatory T cells in cancer suggests more flavors of hypersensitivity type IV. 2018 , 10, 213-219	
211	Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model. 2018 , 67, 653-662	4
210	Repurposing of Drugs for Immunotherapy. 2018 , 143-160	

209	Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle. 2018 , 47, 142-157	16
208	Local Immunotherapies of Cancer. 2018 , 463-481	
207	Strategies to Reduce Intratumoral Regulatory T Cells. 2018 , 483-506	1
206	Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival. 2018 , 36, 128-135	5
205	Role of interferon regulatory factor 1 in governing Treg depletion, Th1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide. 2018 , 142, 976-987	16
204	CD4 and CD8 T lymphocyte interplay in controlling tumor growth. 2018 , 75, 689-713	208
203	Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications. 2018 , 143, 8-15	16
202	Early Phase Cancer Immunotherapy. 2018 ,	1
201	Combinatorial Immunotherapy and Chemotherapy. 2018 , 199-218	4
200	Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer. 2018 , 168, 57-67	12
199	Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. 2018 , 9, 1014-1026	25
198	Single nucleotide polymorphisms of casitas B-lineage lymphoma proto-oncogene-b predict outcomes of patients with advanced non-small cell lung cancer after first-line platinum based doublet chemotherapy. 2018 , 10, 1635-1647	1
197	. 2018 ,	
196	Programmed Death 1 (PD1)-Mediated T-Cell Apoptosis and Cancer Immunotherapy. 2018 , 695-722	0
195	Intraperitoneal oxaliplatin administration inhibits the tumor immunosuppressive microenvironment in an abdominal implantation model of colon cancer. 2018 , 18, 2335-2341	6
194	From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. 2018 , 19,	6
193	The failure of radical treatments to cure cancer: can less deliver more?. 2018 , 6, 69-76	5
192	Sensitivity of CD3/CD28-stimulated versus non-stimulated lymphocytes to ionizing radiation and genotoxic anticancer drugs: key role of ATM in the differential radiation response. 2018 , 9, 1053	27

191	Oncolytic Viruses on Drugs: Achieving Higher Therapeutic Efficacy. 2018 , 4, 1448-1467	23
190	. 2018 , 105 Suppl 1, S121-S131	
189	Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives. 2018 , 66, 1023-1030	19
188	Growth Factor Signaling Pathways and Targeted Therapy. 2018 , 305-322	
187	Antitumor and immune-modulatory efficacy of dual-treatment based on levamisole and/or taurine in Ehrlich ascites carcinoma-bearing mice. 2018 , 106, 43-49	7
186	Commentary: Maintenance of CD8 T Memory Lymphocytes in the Spleen but Not in the Bone Marrow Is Dependent on Proliferation. 2018 , 9, 122	1
185	Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents. 2018 , 9, 594	32
184	The Effect of Light Exposure at Night (LAN) on Carcinogenesis via Decreased Nocturnal Melatonin Synthesis. 2018 , 23,	15
183	Combination therapy: A feasibility strategy for CAR-T cell therapy in the treatment of solid tumors. 2018 , 16, 2063-2070	19
182	Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner. 2018 , 78, 5891-5900	163
181	Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. 2018 , 9, 1739	112
180	Methods for improving the immunogenicity and efficacy of cancer vaccines. 2018 , 18, 765-784	8
179	MUC1 and Cancer Immunotherapy. 2018 , 225-240	4
178	Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer. 2019 , 10, 1654	50
177	Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity. 2019 , 110, 2690-2699	16
176	Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma. 2019 , 10, 2040620719854171	7
175	Synergy Between Low Dose Metronomic Chemotherapy and the pH-centered Approach Against Cancer. 2019 , 20,	3
174	Novel Biomarkers for Personalized Cancer Immunotherapy. 2019 , 11,	21

173	Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression. 2019 , 20,	30
172	Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. 2019 , 121, 123-129	63
171	Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette-Guerin by the modulation of the tumor immune environment. 2019 , 41, 1863-1874	4
170	Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis. 2019 , 25, 1618-1632	20
169	Regulatory T Cells and Their Clinical Applications in Antitumor Immunotherapy. 2019 , 5, 132-139	3
168	Expression of costimulatory and inhibitory receptors in FoxP3 regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches. 2019 , 144, 193-261	9
167	Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?. 2019 , 10, 1181	9
166	Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. 2019 , 110, 2080-2089	254
165	The 100 top-cited studies in cancer immunotherapy. 2019 , 47, 2282-2292	16
164	Ex vivo expanded patient-derived γ -cell immunotherapy enhances neuroblastoma tumor regression in a murine model. 2019 , 8, 1593804	12
163	Turning the Tide Against Regulatory T Cells. 2019 , 9, 279	34
162	Clinical significance of CD8 T cell immunoreceptor with Ig and ITIM domains in locally advanced gastric cancer treated with SOX regimen after D2 gastrectomy. 2019 , 8, e1593807	18
161	Dendritic Cells and Cancer: From Biology to Therapeutic Intervention. 2019 , 11,	57
160	An Evolutionary Constraint-Handling Technique for Parametric Optimization of a Cancer Immunotherapy Model. 2019 , 3, 151-162	5
159	Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience. 2019 , 19, e195-e203	4
158	T-Regulatory Cells In Tumor Progression And Therapy. 2019 , 11, 10731-10747	31
157	Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage Fc β Expression. 2019 , 7, 1876-1890	9
156	GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up. 2019 , 9, 1102	11

155	Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11. 2019 , 42, 180-188	8
154	Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports. 2019 , 20,	3
153	A Porcine Wound Model of Infection. 2019 , 8, 14-27	11
152	Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma. 2019 , 68, 319-329	7
151	The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial. 2019 , 68, 503-515	18
150	Regulatory T cells. 2019 , 33-45	
149	Dendritic cells as cancer therapeutics. 2019 , 86, 77-88	38
148	Immunomodulation in leukemia: cellular aspects of anti-leukemic properties. 2020 , 22, 1-10	10
147	A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. 2020 , 9, 1485-1494	25
146	Antitumor immunity of low-dose cyclophosphamide: changes in T cells and cytokines TGF-beta and IL-10 in mice with colon-cancer liver metastasis. 2020 , 8, 56-65	6
145	In Situ Formed Fibrin Scaffold with Cyclophosphamide to Synergize with Immune Checkpoint Blockade for Inhibition of Cancer Recurrence after Surgery. 2020 , 30, 1906922	33
144	Composition and plasticity of triple-negative breast carcinoma-infiltrating regulatory T cells. 2020 , 128, 260-269	3
143	Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. 2020 , 8,	11
142	Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects. 2020 , 8,	
141	Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade. 2020 , 9, 1830524	17
140	Immunogenic chemotherapy in two mouse colon cancer models. 2020 , 111, 3527-3539	5
139	Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells. 2020 , 11, 1048	10
138	Modulating the Crosstalk between the Tumor and the Microenvironment Using SiRNA: A Flexible Strategy for Breast Cancer Treatment. 2020 , 12,	8

137	A PROGNOSTIC IMMUNOTHERAPY MODEL FOR 4T1 BREAST CANCER WITH COMBINED CYCLOPHOSPHAMIDE AND TLR AGONIST. 2020 , 28, 65-90	1
136	Response Rate and Prognostic Impact of Salvage Chemotherapy after Nivolumab in Patients with Advanced Gastric Cancer. 2020 , 98, 630-636	6
135	CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape. 2020 , 11, 1109	72
134	Targeting Inhibition of Foxp3 by MMP2/9 Sensitive Short Peptide Linked P60 Fusion Protein 6(P60-MMPs) to Enhance Antitumor Immunity. 2020 , 20, e2000098	3
133	The future of cancer immunotherapy: microenvironment-targeting combinations. 2020 , 30, 507-519	194
132	All-Aqueous-Processed Injectable In Situ Forming Macroporous Silk Gel Scaffolds for Minimally Invasive Intracranial and Osteological Therapies. 2020 , 9, e2000879	4
131	Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells. 2020 , 146, 86-96	6
130	Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. 2020 , 108, 1455-1489	7
129	Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance. 2020 , 20, e752-e768	10
128	Regulatory T Cells in Cancer. 2020 , 4, 459-477	35
127	Metronomic anti-angiogenesis: The ideal companion of pH-centered treatments. 2020 , 467-487	
126	Metronomic chemotherapy for patients with metastatic breast cancer: Review of effectiveness and potential use during pandemics. 2020 , 89, 102066	9
125	How does autophagy affect tumor-infiltrating immune cells?. 2020 , 75-84	
124	Krebs Cycle Intermediate-Modified Carbonate Apatite Nanoparticles Drastically Reduce Mouse Tumor Burden and Toxicity by Restricting Broad Tissue Distribution of Anticancer Drugs. 2020 , 12,	4
123	Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF- β Signaling Pathway. 2020 , 21,	8
122	First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. 2020 , 26, 1025-1033	26
121	Red Wine Extract Disrupts Th17 Lymphocyte Differentiation in a Colorectal Cancer Context. 2020 , 64, e1901286	5
120	Evolving Role of Daratumumab: From Backbencher to Frontline Agent. 2020 , 20, 572-587	9

119	Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy - what are we doing; where are we going?. 2021 , 21, 627-637	13
118	Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. 2020 , 22, 7	3
117	Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer. 2021 , 70, 519-531	3
116	Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. 2021 , 8, 1	10
115	Immunochemo combination therapy in cancer treatment. 2021 , 255-273	
114	Nonsurgical treatment of skin cancer with local delivery of bioadhesive nanoparticles. 2021 , 118,	5
113	Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. 2021 , 20, 27	15
112	Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer. 2021 , 6, 36	7
111	Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast. 2021 , 21, 286	6
110	Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives. 2021 , 19, 110	3
109	Tumor resident regulatory T cells. 2021 , 52, 101476	7
108	Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. 2021 , 13,	4
107	Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies. 2021 , 13,	3
106	Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. 2021 , 26, e1508-e1513	5
105	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. 2021 , 27, 4311-4324	5
104	The landscape of bispecific T cell engager in cancer treatment. 2021 , 9, 38	15
103	Monoclonal Antibody Therapies for High Risk Neuroblastoma. 2021 , 15, 205-219	1
102	Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer. 2021 , 11, 684098	8

101	Prospects and Challenges for T Cell-Based Therapies of HCC. 2021 , 10,	2
100	The potential of CAR T cell therapy for prostate cancer. 2021 , 18, 556-571	8
99	Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits. 2021 , 13,	2
98	The impact of the host intestinal microbiome on carcinogenesis and the response to chemotherapy. 2021 , 17, 4371-4387	1
97	The Role of Microbiota in Gastrointestinal Cancer and Cancer Treatment - Chance or Curse?. 2021 ,	4
96	Harnessing the Immune System to Fight Multiple Myeloma. 2021 , 13,	1
95	Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma. 2021 , 13,	3
94	Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy. 2021 , 11, 721249	0
93	Molecular oncology in gynecologic cancer. 2022 , 606-617.e3	
92	Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete FreundB adjuvant, cyclophosphamide, and polyICLC (Mel63). 2021 , 9,	6
91	Effect of the drug cyclophosphamide on the activity of porcine kidney betaine aldehyde dehydrogenase. 2021 , 476, 1467-1475	1
90	Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment. 2021 , 13,	5
89	The Evolving Role of Nanoparticles in Bacteria Mediated Cancer Therapy. 2021 , 331-347	
88	The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine. 2021 , 10, 1924492	2
87	Dendritic Cell Vaccines in Cancer: Obstaclesto Overcome. 2009 , 309-330	2
86	Peptide and Protein-Based Cancer Vaccines. 2013 , 111-146	1
85	Metronomic Low-Dose Antiangiogenic Chemotherapy in Mice and Man. 2008 , 277-296	1
84	Development and Evolution of the Concept of Metronomic Chemotherapy: A Personal Perspective. 2014 , 3-21	2

83	Effects of Metronomic Chemotherapy on Immunity. 2014 , 39-51	1
82	The Biomodulatory Capacities of Low-Dose Metronomic Chemotherapy: Complex Modulation of the Tumor Microenvironment. 2010 , 243-262	10
81	Effect of Chemotherapy on the Tumor Microenvironment and Anti-tumor Immunity. 2013 , 1-28	2
80	[Vaccine strategies against melanoma]. 2006 , 22, 183-7	2
79	Supplementation of l-arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy. 2020 , 111, 2248-2258	8
78	Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. 2021 , 27, 1278-1286	11
77	Indoleamine 2,3-dioxygenase and tumor-induced tolerance. 2007 , 117, 1147-54	785
76	Development of TLR9 agonists for cancer therapy. 2007 , 117, 1184-94	320
75	Dendritic cell-derived exosomes for cancer therapy. 2016 , 126, 1224-32	267
74	Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. 2009 , 4, e6982	70
73	In vivo expansion of naïve CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administration. 2012 , 7, e30422	17
72	Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response. 2013 , 8, e83384	65
71	Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment. 2014 , 9, e109992	25
70	Phytotherapy and phytopharmacology for reduction of cyclophosphamide-induced toxicity in the male urinary system. 2017 , 6, 164-170	4
69	Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. 2013 , 33, 1-21	36
68	Excellent response to chemotherapy post immunotherapy. 2017 , 8, 91795-91802	39
67	Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting. 2018 , 9, 3576-3589	14
66	Immunological monitoring for prediction of clinical response to antitumor vaccine therapy. 2018 , 9, 24381-24390	

65	Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients. 2018 , 9, 34009-34021	13
64	Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma. 2020 , 11, 1618-1628	6
63	Chemotherapy and tumor immunity: an unexpected collaboration. 2008 , 13, 249-57	38
62	Regulatory T Cells in the Human Immune System. 2010 , 53, 737	1
61	[Immunoregulatory function of Radix Glycyrrhizae polysaccharide in tumor-bearing mice]. 2010 , 8, 363-7	3
60	Alpha-fetoprotein specific CD4 and CD8 T cell responses in patients with hepatocellular carcinoma. 2010 , 2, 256-60	13
59	The mechanism of the anticancer function of M1 macrophages and their use in the clinic. 2012 , 31, 557-63	19
58	Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. 2021 , 6,	0
57	CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges. 2021 , 101, 108260	2
56	Regulatory T Cells and Tumour Immunotherapy. 2008 , 379-392	
55	Effects of Tumor Microenvironment on Immunity and Consequent Clinical Considerations. 2009 , 157-179	
54	The Effect of Gefitinib on Immune Response of Human Peripheral Blood Monocyte-Derived Dendritic Cells. 2010 , 69, 456	
53	Cancer Immunology, Immunotherapeutics, and Vaccine Approaches. 2010 , 305-319	
52	Transcriptional Modulation Using Histone Deacetylase Inhibitors for Cancer Immunotherapy. 2011 , 307-322	
51	Targeting regulatory T cells and other strategies to enable cancer vaccines. 2011 , 182-201	
50	Adoptive Immunotherapy of Melanoma. 2012 , 439-465	
49	Influence of Different Stem Cell Mobilization Strategies on Graft Composition and Outcome of Autologous or Allogeneic Transplantation. 2012 , 165-200	
48	Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators. 2012 , Suppl 5, 004	2

47	Immunotherapy of Hepatocellular Carcinoma. 2012 , 299-337	
46	Immunology of brain tumors and implications for immunotherapy. 2012 , 125-137	
45	Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies. 2013 , 455-474	
44	Activation of Immune-Mediated Tumor Cell Death by Chemotherapy. 2013 , 373-399	
43	Dendritic Cells for Cancer Immunotherapy. 2013 , 251-270	
42	Therapeutic Targeting Regulatory T Cells in Tumor. 2013 , 585-602	
41	ChemImmunoModulation: Focus on Myeloid Regulatory Cells. 2013 , 603-619	
40	Cancer Immune Modulation and Immunosuppressive Cells: Current and Future Therapeutic Approaches. 2014 , 187-214	
39	Metronomic Chemotherapy in Non-Small-Cell Lung Cancer. 2014 , 217-226	
38	The role of gut microbiota in forming a response to immunotherapy of malignant neoplasms: problem state. 2018 , 128-133	
37	Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma. 2020 , 19, 2943-2949	2
36	Breast cancer immune microenvironment: from pre-clinical models to clinical therapies. 2021 , 1	1
35	Adoptive Cellular Therapy for the Treatment of Cancer. 2007 , 343-361	
34	Metronomic Antiangiogenic Chemotherapy: Questions and Answers. 2008 , 593-607	
33	Mechanisms of malignant glioma immune resistance and sources of immunosuppression. 2006 , 10, 133-146	84
32	Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors. 2015 , 7, 1022-38	5
31	Regulatory T Cells in Gynecologic Cancer. 2018 , 6, 34-42	11
30	Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives. 2021 , 13,	0

29	Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment.. 2021 , 12, 832942	3
28	Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis.. 2022 , 10,	1
27	Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment.. 2022 , 12,	1
26	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy.. 2022 , 236, 108111	6
25	Tumor lysates cancer vaccine. 2022 , 21-49	
24	Transplantation of autologous bone marrow pre-loaded with oncolytic myxoma virus is efficacious against drug-resistant V κ *MYC mouse myeloma.. 2022 , 13, 490-504	
23	Unexpected response to fourth-line paclitaxel in a patient with metastatic oropharyngeal squamous cell carcinoma, immunotherapy-refractory: a case report.. 2022 ,	0
22	Low-dose cyclophosphamide combined with IL-2 inhibits tumor growth by decreasing regulatory T cells and increasing CD8+ T cells and natural killer cells in mice.. 2022 , 227, 152212	0
21	Comparison Between Nr4a Transcription Factor Regulation and Function in Lymphoid and Tumor Treg Cells.. 2022 , 13, 866339	
20	Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.. 2022 ,	0
19	Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.. 2022 , 183, 287-315	
18	Identification of EPZ004777 and FG2216 as inhibitors of TGF- β induced Treg cells by screening a library of epigenetic compounds.. 2022 , 301, 120643	
17	The Nitrogen Mustards. 2022 , 74, 552-599	2
16	Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF- β signaling in regulatory T cells. 2022 , 39, 110986	7
15	Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial. 2022 , 14, 3808	1
14	Potential influence of anaesthesia techniques on the recurrence and progression after resection of non-muscle-invasive bladder cancer: a propensity score-matched analysis. 2022 , 22,	0
13	Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy. 2022 , 14, 1768	1
12	Neuroimmune crosstalk and its impact on cancer therapy and research. 2022 , 13,	

11	Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics. 2022 , 8, e10450	0
10	Interaction between gut microbiota and tumour chemotherapy.	0
9	Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. 2022 , 11,	4
8	Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints. 2022 , 14, 5332	1
7	Minimal Residual Disease (MRD) and a New Immunotherapy in Locally Advanced Prostate Cancer. 2022 ,	0
6	Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy. 2022 ,	1
5	A modulatory effect of L-arginine supplementation on anticancer effects of chemoimmunotherapy in colon cancer-bearing aged mice. 2022 , 113, 109423	0
4	Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment. 2022 , 29, 8975-9005	0
3	The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment. 13,	0
2	Boosting In-Vivo Anti-Tumor Immunity with an Oral Microparticulate Breast Cancer Vaccine and Low-Dose Cyclophosphamide. 2023 , 11, 543	0
1	Establishing the applicability of cancer vaccines in combination with chemotherapeutic entities: current aspect and achievable prospects. 2023 , 40,	0